mCRPC Treatment Live:

Introducing a new option before chemotherapy for the treatment of mCRPC

by Paul R. Sieber, MD

In this presentation, Paul R. Sieber, MD reviews patient history and treatment options for two mCRPC patients.

The slide lecture will take approximately 8 minutes to complete.

Clinical approaches to androgen resistance

by Charles J. Ryan, MD

In this presentation, Charles J. Ryan, MD  provides the first comprehensive review of the emerging understanding of androgen resistance.

The slide lecture will take approximately 25 minutes to complete.

Updated interim analysis (55% OS) of COU-AA-302, a randomized phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy

by Charles J. Ryan, MD

In this presentation, Charles J. Ryan, MD presents the latest clinical results (February 2013) from a randomized phase III study of the use of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy. 

The slide lecture will take approximately 22 minutes to complete.

Treatment of chemotherapy-naive metastatic castration-resistant prostate cancer

by Bryan Mehlhaff, MD

In this presentation, Bryan Mehlhaff, MD, discusses the treatment history of a 49-year-old prostate cancer patient from the time of diagnosis 2001 through 2012. 

The case lecture presentation will take approximately 12 minutes to complete.

The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer

by Charles J. Ryan, MD

In this presentation, Dr. Ryan discusses quality-of-life results, demonstrating a more real-world view of how patients actually feel and function when receiving abiraterone acetate therapy.

The case lecture presentation will take approximately 20 minutes to complete.

Maximum androgen blockade with abiraterone

by Charles J. Ryan, MD

In this presentation, Charles J. Ryan, MD, Associate Professor of Medicine and Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco discusses Maximum Androgen Blockade with Abiraterone

The case lecture presentation will take approximately 30 minutes to complete.